Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 24 October 2023At today’s Investor Day, Galenica is presenting its updated mid-term guidance. Galenica is raising its mid-term growth forecast and now expects annual net sales growth of between 3% and 5%. Furthermore, Galenica is confirming its mid-term targets for return on sales (ROS)¹ at over 9.5% in the Products & Care segment and up to 2% in the Logistics & IT segment. At its Investor Day, Galenica will also provide in-depth insights into its strategic programmes and show how it intends to to tap into additional growth potential through innovation.
Galenica is raising its mid-term growth forecast and now expects net sales to grow by 3% to 5% in the next years. To date, Galenica had expected sales to grow faster than the expected market growth of 1% to 2%.
Galenica is confirming its mid-term targets for return on sales (ROS)1 at over 9.5% in the Products & Care segment and up to 2% in the Logistics & IT segment. Galenica aims to achieve these targets in its centenary year 2027 with an EBIT2 of over CHF 250 million. Due to an intensive final phase of the ERP project in the Logistics & IT segment, scheduled to be completed in 2025, ongoing investments in the digital Omni-Channel infrastructure as well as further investments in staff as a basis for the Group’s successful further development, Galenica expects a stable development of its return on sales (ROS)1 up to 2025.
Galenica assumes that the level of investments3 will remain stable over the next years and continues to aim for net debt2 of around +/-2× EBITDA2. Galenica continues to pursue a policy of at least stable dividends that grow in line with results.
The current guidance for the 2023 financial year, with sales growth of between 3% and 6% and EBIT2 at roughly prior year level (based on the restated figures from the previous year) remains unchanged.
Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 8 August 2023In the first half of 2023, Galenica increased consolidated net sales by 5.5% compared to the first half of the previous year to CHF 1,851.2 million. The “Logistics & IT” segment in particular posted strong growth of 5.8%. The “Products & Care” segment also performed well with sales growth of 4.2%, supported by the strong performance of 19.8% in the “Products & Brands” sector.
Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 25 July 2023Due to special factors in the 2023 half-year financial statements, Galenica is lowering its EBIT guidance for 2023 and now expects adjusted² EBIT to be roughly at prior-year level on the basis of the restated¹ prior-year figures. Galenica previously assumed an EBIT growth of between 4% and 7%. On the other hand, Galenica confirms its 2023 outlook for consolidated net sales (growth between 3% and 6%) and dividend (at least at the same level as the previous year).
News, Friday, 3 November 2023The time has finally come: After a three-year renovation phase, the team from the Amavita Bahnhof Apotheke in Zurich main station is able to welcome its customers back to their original location in renovated and redesigned premises. As part of the renovation work on the south wing of Zurich main station, the pharmacy had to move to the temporary site in Wannerhalle in March 2020.
The past few weeks have been intense for the pharmacy team. In addition to ensuring the operation of the pharmacy at the provisional site, many details still had to be decided, the renovated premises had to be furnished and around 60,000 products organised. The pharmacy in the historic building is now shining in new splendour.
It now has 16 cash registers, three consultation rooms, a medication robot and a laboratory and analysis area. Clearly marked zones with different product categories such as medicines, dermocosmetics and natural remedies help customers to find their way around.
The benefits of this design are, above all, more space for customers, more efficient processes and areas for private patient consultations. The fact that there is more time and space available for personal advice to customers is also a major advantage, especially at the moment, because the official flu vaccination campaign is about to start. And thanks to its central location, the Amavita Bahnhof Apotheke is also an important location for healthcare services such as vaccinations and a popular point of contact for health-related issues.
The renovated and redesigned premises of the Amavita Bahnhof Apotheke mean greater comfort not only for customers, but also for employees. Over the past three years, they have often been confronted with long queues and high noise levels, particularly at rush hour. That’s why the whole team was eagerly looking forward to today’s opening day. Comanagers Megy Keller and Yves Platel comment on the good mood: “Our employees are thrilled and, above all, relieved after three years of waiting. They can now also enjoy a beautiful break room, a relaxation room and an inviting meeting room.”
On today’s opening day, customers can look forward to a professional and motivated team and a wide range of products (including a complementary department offering custom-made preparations), as well as numerous surprises and a gift.
Some facts & figures about the “new” Amavita Bahnhof Apotheke:
- Open 365 days a year, from 7 a.m. through to midnight
- Over 700 m2 distributed over two floors, making it Galenica's largest pharmacy in terms of floor area
- Around 1,500 customers per day
- Approx. 70,000 medicines/products in the range
- Health services such as vaccinations, AllergyCheck (AllergieCheck), CardioTest® (HerzCheck®), SkinCheck (HautCheck), blood tests
- More than 10,000 documents and clarifications per year
- Around 100 employees who are able to provide advice in a total of 23 languages
News, Tuesday, 8 November 2022In 2023, Galenica will grant all its employees a fixed cost-of-living adjustment. It is investing over CHF 14 million, thus increasing the payroll for its employees by a total of 3.1 per cent. Additional measures are being implemented for pharmacy staff to increase its attractiveness as an employer.
News, Wednesday, 21 September 2022Omni-channel – i.e. the link between online and offline – is a key element of the Galenica strategy. Contrary to earlier expectations, the Careproduct product range cannot be optimally integrated at Galenica. For this reason, Galenica is selling its subsidiary Careproduct to SAB Management Holding Ltd. and its owner Bruno Sauter, effective 20 September 2022.
Media conferences and events
- March 12, 2024Publication of Galenica Group annual results 2023
- April 10, 2024Annual General Meeting of Galenica Ltd.